Transactions
10
Insider / Merck & Co., Inc.
Litchfield Caroline
EVP & CFO at Merck & Co., Inc.
- Company
- Merck & Co., Inc.
- First filing on record
- January 28, 2026
- Latest trade on record
- May 5, 2026
- SEC filings
- EDGAR ↗
Litchfield Caroline, EVP & CFO at Merck & Co., Inc., has disclosed 10 transactions in MRK, VZ since January 28, 2026: 0 purchases (0 open-market buys) and 2 sales, worth about $9.6M at the reported prices. The latest was filed May 7, 2026, 2 days after the trade.
Open-market buys
0
Sales
2
Avg. disclosure lag
1.9d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Litchfield Caroline made no purchases and 2 sales worth $5.2M, plus 8 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Litchfield Caroline has traded 1 stock on record; the largest by dollars is MRK.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 4 | 83,388 | $1.7M |
| M | Option exercise or conversion | 4 | 91,864 | $2.7M |
| F | Shares withheld for tax | 1 | 1,938 | $213K |
| S | Open-market sale | 1 | 41,997 | $5.0M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 10 | 0 | 2 · $5.2M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MRK | Other A | May 5, 2026 | May 7, 2026 | 2d | 46,566 | — | — | derivative | Form 4 ↗ | |
| MRK | Other A | May 5, 2026 | May 7, 2026 | 2d | 15,908 | — | — | derivative | Form 4 ↗ | |
| MRK | Option / conversion M | April 29, 2026 | May 1, 2026 | 2d | 3,935 | — | — | derivative | Form 4 ↗ | |
| MRK | Sell F | April 29, 2026 | May 1, 2026 | 2d | 1,938 | $110 | $213K | Form 4 ↗ | ||
| MRK | Option / conversion M | April 29, 2026 | May 1, 2026 | 2d | 3,935 | $110 | $433K | Form 4 ↗ | ||
| VZ | Other A | April 1, 2026 | April 2, 2026 | 1d | 5,062 | — | — | indirectderivative | Form 4 ↗ | |
| MRK | Option / conversion M | February 4, 2026 | February 6, 2026 | 2d | 41,997 | — | — | derivative | Form 4 ↗ | |
| MRK | Sell S | February 4, 2026 | February 6, 2026 | 2d | 41,997 | $120 | $5.0M | Form 4 ↗ | ||
| MRK | Option / conversion M | February 4, 2026 | February 6, 2026 | 2d | 41,997 | $53 | $2.2M | Form 4 ↗ | ||
| MRK | Other A | January 26, 2026 | January 28, 2026 | 2d | 15,852 | $107 | $1.7M | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 7, 2026 | Form 4 | 0000310158-26-000135 | 2 | published | EDGAR ↗ |
| May 1, 2026 | Form 4 | 0000310158-26-000082 | 3 | published | EDGAR ↗ |
| April 2, 2026 | Form 4 | 0001854928-26-000002 | 1 | published | EDGAR ↗ |
| February 6, 2026 | Form 4 | 0000310158-26-000038 | 3 | published | EDGAR ↗ |
| January 28, 2026 | Form 4 | 0000310158-26-000018 | 1 | published | EDGAR ↗ |
Other insiders at Merck & Co., Inc.
- Malady Kyle EVP and Group CEO-VZ Business 50 rows
- Russo Joseph J. EVP&Pres-Global Networks&Tech 41 rows
- Skiadas Anthony T EVP and CFO 40 rows
- Stillwell Mary-Lee SVP and Controller 40 rows
- Venkatesh Vandana EVP-PubPol&ChiefLegalOfficer 40 rows
- Vestberg Hans Erik Director 37 rows
- Hammock Samantha EVP & Chief HR Officer 34 rows
- Karsanbhai Surendralal Lanca Director 30 rows
- SCHULMAN DANIEL H Director 30 rows
- MANN JENNIFER K Executive Vice President 24 rows
Everyone on file, with contracts and lobbying under the company's name: Merck & Co., Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 10 | January 28, 2026 | May 7, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.